29-04-2025 18:00 via medscape.com

FDA Okays Upadacitinib for Giant Cell Arteritis

This is the first and only oral JAK inhibitor indicated for giant cell arteritis, according to the manufacturer AbbVie.Medscape Medical News
Read more »

Nurse news



Immigrants Do Not Threaten America’s Health: Ethicist
Immigrants Do Not Threaten America’s Health: Ethicist
It’s Complicated: Treating NSCLC Without a Clear Target
It’s Complicated: Treating NSCLC Without a Clear Target
AAN 2025: The Impact of Updated Diagnostic Criteria in RRMS
AAN 2025: The Impact of Updated Diagnostic Criteria in RRMS
Ivarmacitinib Provides Relief in Atopic Dermatitis Study
Ivarmacitinib Provides Relief in Atopic Dermatitis Study
Emerging Biomarkers and Treatments in Anal Cancer
Emerging Biomarkers and Treatments in Anal Cancer
Highlights in Myasthenia Gravis From AAN 2025
Highlights in Myasthenia Gravis From AAN 2025
Real-World Data Support Febuxostat’s Cardiovascular Safety
Real-World Data Support Febuxostat’s Cardiovascular Safety
Ritlecitinib plus nbUVB improves vitiligo repigmentation
Ritlecitinib plus nbUVB improves vitiligo repigmentation
US Alzheimer’s Prevalence Surpasses 7 Million
US Alzheimer’s Prevalence Surpasses 7 Million
Atopy Rises in Indian Immigrant Kids, Study Finds
Atopy Rises in Indian Immigrant Kids, Study Finds
Fewer Permanent Nurses on Wards Link to Higher Death Rates
Fewer Permanent Nurses on Wards Link to Higher Death Rates
Doctor Aids In-Air Emergency Birth — With a Wild Plot Twist
FDA Approves First One-Time Treatment for RDEB Wounds
Is BMI Still the Best Tool for Assessing Weight?
Desktop versie